Alkermes entered May with a catalyst in hand. Q1 results dropped on May 5, topping both revenue and earnings estimates, and the stock responded with a 6% gain on the day. The question now is whether the renewed analyst conviction that followed the print is enough to keep shorts — still meaningfully elevated at 12.4% of the float — on the back foot.
The analyst response to Q1 was unusually unified. Three firms raised targets on May 6 alone. UBS lifted its buy-rated target from $42 to $48. Needham moved from $45 to $50 while holding its buy. Wells Fargo edged from $43 to $44 with an Overweight. The mean price target across the covering universe is now $45.24 — roughly 25% above the current $36.25 close. Bank of America remains the most prominent hold-out, sitting at Neutral with a $36 target after raising modestly from $34 in April. So the directional tilt is bullish, but the Street isn't monolithic. The bulls see Lumryz growing toward $265–275 million in annualized sales and a clear EPS growth runway through product diversification. The bears worry about the orexin competitive landscape, Medicaid exposure, and what the royalty business looks like long-term.
Valuation has moved alongside the stock. The EV/EBITDA multiple is running near 15.5x, up about 0.7x over the last month. The PE ratio at face value looks stretched — above 90x on trailing earnings — but that number is heavily distorted by ALKS's recent earnings history; the EPS surprise factor score ranks in the 98th percentile of the universe, signalling the company has repeatedly exceeded what analysts modelled. The forward earnings momentum scores are weaker, with 30-day and 90-day EPS momentum in single-digit percentiles, suggesting the revision cycle has been cautious ahead of this print rather than anticipatory.
Short positioning tells a more complicated story for the bulls. At 12.4% of free float and edging higher — up about 3.2% on the week before the earnings pop — ALKS carries a meaningful short overhang. The ORTEX short score reached 67 on May 5, the highest reading in the tracked history, and has climbed steadily over the past two weeks from around 64. FINRA's most recent fortnightly count put days to cover at 8.2, and SI was already near 19.7 million shares as of the April 15 settlement date. That said, borrowing costs remain near rock-bottom: cost to borrow has drifted lower over the past month to just 0.47%, down about 15%. Availability is not particularly tight — the borrow market is comfortable, not stressed. There is no indication of forced covering pressure. Shorts are present and growing modestly, but the cost to maintain those positions is essentially zero.
Options positioning is broadly neutral. The put/call ratio at 1.21 is fractionally below its 20-day average of 1.23 — a near-flat z-score of -0.1 — suggesting no material hedging panic or speculative call-buying surge accompanied the earnings release. The 52-week PCR range is wide (0.13 to 3.18), putting current readings comfortably in neutral territory. Peer CYTK surged 27% on the week, the sharpest move among correlated names; MLYS was also up double digits. ALKS's 6% weekly gain looks measured by comparison, which may reflect lingering short resistance rather than a lack of fundamental catalyst.
What to watch next: the next earnings event is slated for late July. Between now and then, the tension between a freshly validated bull case and a still-elevated short position — with borrowing costs too low to force a cover — will determine whether the 12.4% float short acts as a persistent drag or becomes the fuel for a more decisive move.
See the live data behind this article on ORTEX.
Open ALKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
